Document is current
Any future updates will be listed below
-
Authors
Lee, Minji K. https://orcid.org/0000-0002-1301-4319
Mitchell, Sandra A.
Basch, Ethan
Mazza, Gina L.
Langlais, Blake T.
Thanarajasingam, Gita
Ginos, Brenda F.
Rogak, Lauren
Meek, Eric A.
Jansen, Jennifer
Deal, Allison M.
Carr, Philip
Blinder, Victoria S.
Jonsson, Mattias
Mody, Gita N.
Mendoza, Tito R.
Bennett, Antonia V.
Schrag, Deborah
Dueck, Amylou C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03249090 at ClinicalTrials.govnct02158637 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of Providing an Automated Telephone Option to Report Weekly Patient-Reported Outcome Measures in the PRO-TECT Trial (AFT-39) on Disparity Gaps in Symptom Management and Outcomes
https://doi.org/10.1200/cci-25-00046
Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39)
https://doi.org/10.1200/op-24-00627
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
https://doi.org/10.1007/s11136-024-03819-5
Documents that mention this clinical trial
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
https://doi.org/10.1007/s11136-024-03819-5
-
Funding
Funding for this research was provided by:
National Cancer Institute (U01 CA233046, HHSN261200800043C, 5-P30-CA016086)
- License Information
-
More Information
Article History
Accepted: 21 October 2024
First Online: 6 November 2024
Declarations
:
: EB reports research funding to the University of North Carolina from the National Cancer Institute and Patient-Centered Outcomes Research Institute, and direct funding as a scientific advisor to Sivan, Carevive, Resilience, N-Power, Navigating Cancer, and AstraZeneca. DS reports research funding to the Dana Farber Cancer Institute from the National Cancer Institute, Patient-Centered Outcomes Research Institute, and American Association of Cancer Research, and Grail. She reports serving as an uncompensated advisor to Grail and as a compensated advisor to the Centers for Medicare and Medicaid Services, and to several states and International Governments. She reports compensation from JAMA for editorial services. Other authors declare they have no competing interests. The views expressed here are those of the authors only and do not represent any official position of the National Cancer Institute or National Institutes of Health.
: This was a secondary analysis of data from prospective trials. For the original validation study, institutional review board (IRB) approval was obtained at all sites and at the National Cancer Institute, and all participants provided written informed consent. For the PRO-TECT data, the trial protocol and consent were approved by central and local IRBs.
